Central Nervous System News and Research

RSS

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is contributing to rapid market development.

12 Jan 2005

Scientists identify a protein that regulates alcohol-withdrawal seizures

Seizures are the most life-threatening, as well as disconcerting, symptoms of withdrawal in people who are alcoholics and who abruptly stop drinking. Heavy consumption of alcohol, or ethanol, the substance in beer, wine and liquor that is addictive, leads to changes in the brain.

10 Jan 2005

Restless legs syndrome is underdiagnosed in kids

A new Mayo Clinic study has for the first time established rates of restless legs syndrome in children, finding that almost 6 percent of children seen in Mayo's sleep clinic have the disease.

28 Dec 2004

Paclitaxel may benefit Alzheimer's and Parkinson's movement disorders

Angiotech Pharmaceuticals have announced that a preclinical study published in today's early edition of the Proceedings of the National Academy of Sciences highlights the positive effects of Paxceed on movement disorders commonly seen in diseases known as taupathies, such as Alzheimer's and Parkinson's.

27 Dec 2004

FDA approves Enablex for the treatment of overactive bladder

Novartis Pharmaceuticals Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Enablex® (darifenacin) extended-release tablets (7.5mg and 15mg) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency.

22 Dec 2004

Turning off cell suicide switch fails to stop prion damage

Researchers knew that prions, the misfolded proteins that cause mad cow disease and other brain disorders, were killing off a class of important brain cells in a transgenic mouse model. But when they found a way to rescue those cells, they were astonished to discover the mice still became sick.

21 Dec 2004

DLX5 gene may play a role in the pathology of Rett Syndrome

A research team led by Terumi Kohwi-Shigematsu of the Life Sciences Division of Lawrence Berkeley National Laboratory has identified a gene, DLX5, that may play a role in the pathology of Rett Syndrome, a devastating neurological disorder diagnosed almost exclusively in girls.

20 Dec 2004

Tentative approval for Topiramate Tablets

Ranbaxy Pharmaceuticals announced tentative approval from the U.S. Food and Drug Administration to manufacture and market Topiramate Tablets, 25 mg, 100 mg, and 200 mg. Total annual market sales for Topiramate were $1,184 million with sales of these three strengths of tablets totaling $1,129 million.

20 Dec 2004

Childhood cancer slowly increasing over the past 3 decades

Research from 19 European countries in this week’s issue of THE LANCET documents how childhood cancer, while still rare, has been slowly increasing over the past 3 decades.

13 Dec 2004

New advances in sickle cell disease

Excruciating pain episodes, recurrent pneumonias, strokes, severe infections, chronic hemolytic anemia, and secondary pulmonary hypertension are common complications of sickle cell disease, a life-threatening inherited defect in blood that causes normally disc-shaped red blood cells to take on a sickle shape.

6 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Novel anti-obesity compound shows promise for treatment of obesity

Arena Pharmaceuticals announced today results from the dosing phase of its Phase 1b clinical trial of APD356, an orally administered small molecule designed to regulate satiety (and perhaps metabolism) for the treatment of obesity.

30 Nov 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

New research may lead to new treatments for spinal cord injury and multiple sclerosis

For the first time, researchers have used human embryonic stem cells to create new insulating tissue for nerve fibers in a live animal model – a finding that has potentially important implications for treatment of spinal cord injury and multiple sclerosis.

23 Nov 2004

Capsules may be effective in treating bipolar disorder

University of North Carolina at Chapel Hill researchers have announced study results finding that a formulation of three-beaded extended-release carbamazepine capsules (ERC-CBZ) was effective, safe and tolerable in the treatment of bipolar I disorder

19 Nov 2004

Statement from U.S. Department of Agriculture on an inconclusive BSE test result

Statement by Andrea Morgan, Associate Deputy Administrator, Animal and Plant Health Inspection Service, U.S. Department of Agriculture on an Inconclusive BSE Test Result.

18 Nov 2004

Early infection in low-birth-weight infants linked with poor neurodevelopmental

Extremely low-birth-weight (ELBW) infants who have an infection during their hospitalization following birth are more likely to have adverse neurodevelopmental outcomes than those infants who do not have an infection, according to a study in the November 17 issue of JAMA.

17 Nov 2004

36% of cancer patients ages 65 and older participate in clinical trials

A new study finds that only 36% of cancer patients ages 65 and older participate in clinical trials, despite making up 60% of the U.S. cancer population. The study will be published November 15 in the Journal of Clinical Oncology (JCO).

14 Nov 2004

Prenatal alcohol exposure has effects far beyond fetal alcohol syndrome

Numerous studies have documented IQ deficits in children with fetal alcohol syndrome (FAS). Little research, however, has found IQ deficits in children with alcohol-related neurodevelopmental disorder (ARND), who generally exhibit less severe neurobehavioral deficits than children with FAS.

14 Nov 2004

Sex genes of infectious fungus closely resemble human Y chromosome

Fungi and animals, including humans, have a lot in common when it comes to the arrangement of genes that determine their sex, according to new work by Howard Hughes Medical Institute geneticists at the Duke University Medical Center.

10 Nov 2004